jeffrey weber, md, phd: durability of a response to targeted therapy combination
Published 7 years ago • 46 plays • Length 1:01
Download video MP4
Download video MP3
Similar videos
-
1:44
jeffrey weber, md, phd: predicting durable responses to targeted therapy
-
2:20
jeffrey weber, md, phd: the association between durable response and low disease burden
-
1:23
dr. jeffrey weber on the keys to targeted treatments
-
1:28
jeffrey weber, md, phd: factors to consider when determining treatments
-
0:55
jason luke, md: durability of a response to targeted therapy combination
-
2:34
jeffrey weber, md, phd explains the importance of administering ipilimumab with a pd-l1 inhibitor
-
1:46
jeffrey weber, md, phd explains the importance of testing for nras as compared with a braf biomarker
-
1:11
jeffrey weber, md, phd: the impact of moderate level of disease burden
-
1:28
jeffrey weber, md, phd: the impact of braf/mek inhibitors in melanoma
-
2:10
dr. jeffrey s. weber on why the results of checkmate-064 were surprising
-
1:03
dr. weber on risk and benefits with immunotherapy combos in melanoma
-
1:54
jeffrey weber, md, phd, discusses the efficacy of checkpoint inhibitors and immunotherapy
-
2:19
jeffrey weber, md, phd: factors to consider when determining treatment
-
1:44
dr. jeffrey weber on optimal therapy sequences in advanced melanoma
-
1:26
jeffrey weber, md, phd provides interpretation of the nemo trial results
-
0:49
dr. weber on emerging therapies in melanoma
-
1:08
dr. weber discusses toxicity of immunotherapies in melanoma
-
0:42
2022 ime dr. jeffrey s. weber, md, phd invites you to the 18th annual ime conference on melanoma
-
1:23
jeffrey weber, md, phd discusses the long term side effects with immunotherapies
Clip.africa.com - Privacy-policy